首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9
【24h】

S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9

机译:S100A4通过基质金属蛋白酶9的转录调控加速人类前列腺癌的发生和侵袭

获取原文
获取原文并翻译 | 示例
           

摘要

We previously showed that the calcium-binding protein S100A4 is overexpressed during the progression of prostate cancer (CaP) in humans and in the TRAMP (transgenic adenocarcinoma of the mouse prostate) mouse model. We tested a hypothesis that the S100A4 gene plays a role in the invasiveness of human CaP and may be associated with its metastatic spread. We observed that siRNA-mediated suppression of the S100A4 gene significantly reduced the proliferative and invasive capability of the highly invasive CaP cells PC-3. We evaluated the mechanism through which the S100A4 gene controls invasiveness of cells by using a macroarray containing 96 well characterized metastatic genes. We found that matrix metalloproteinase 9 (MMP-9) and its tissue inhibitor (TIMP-1) were highly responsive to S100A4 gene suppression. Furthermore, S100A4 suppression significantly reduced the expression and pro-teolytic activity of MMP-9. By employing an MMP-9-promoter reporter, we observed a significant reduction in the transcriptional activation of the MMP-9 gene in S100A4-siRNA-transfected cells. Cells overexpressing the S100A4 gene (when transfected with pcDNA3.1-S100A4 plasmid) also significantly expressed MMP-9 and TIMP-1 genes with increased proteolytic activity of MMP-9 concomitant to increased transcriptional activation of the MMP-9 gene. S100A4-siRNA-transfected cells exhibited a reduced rate of tumor growth under in vivo conditions. Our data demonstrate that the S100A4 gene controls the invasive potential of human CaP cells through regulation of MMP-9 and that this association may contribute to metastasis of CaP cells. We suggest that S100A4 could be used as a biomarker for CaP progression and a novel therapeutic or chemopreventive target for human CaP treatment.
机译:我们先前显示,钙结合蛋白S100A4在人类和TRAMP(小鼠前列腺的转基因腺癌​​)小鼠模型的前列腺癌(CaP)进程中过表达。我们测试了一个假设,即S100A4基因在人类CaP的侵袭性中起作用,并且可能与其转移扩散有关。我们观察到,siRNA介导的S100A4基因抑制作用显着降低了高侵袭性CaP细胞PC-3的增殖和侵袭能力。我们通过使用包含96个特征明确的转移基因的大阵列,评估了S100A4基因控制细胞侵袭性的机制。我们发现基质金属蛋白酶9(MMP-9)及其组织抑制剂(TIMP-1)对S100A4基因抑制高度敏感。此外,S100A4抑制显着降低了MMP-9的表达和蛋白水解活性。通过使用MMP-9启动子报告基因,我们观察到S100A4-siRNA转染的细胞中MMP-9基因的转录激活显着减少。过度表达S100A4基因的细胞(当用pcDNA3.1-S100A4质粒转染时)也显着表达MMP-9和TIMP-1基因,MMP-9的蛋白水解活性增强,并伴随着MMP-9基因的转录激活增加。 S100A4-siRNA转染的细胞在体内条件下显示出降低的肿瘤生长速率。我们的数据表明,S100A4基因通过调节MMP-9来控制人CaP细胞的侵袭潜力,并且这种关联可能有助于CaP细胞的转移。我们建议S100A4可以用作CaP进展的生物标志物和人类CaP治疗的新型治疗或化学预防靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号